Scouting report · HELP

Michael I. Halstead

Ex-President of Intra-Cellular Therapies; Helus Pharma CEO since August 2026

Born / age
(53)
Role
Chief Executive Officer and Director
In the role
2 mo
Education
BA Boston University
Front Office rank
not ranked yet
HELP
Cybin Inc.Biotech binary
Title
Chief Executive Officer and Directorsrc
In role
since 2026-08 (2 mo)
Stake value$2.3m168,568 shares · as of 21 Sep 2026
—thin record

Scouting sheetas of 24 Sep 2026

Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company five-year record: neutral — inherited: the five-year record is mostly a predecessor's
Pay design—tsr, time only
Skin in the game—no holding or price on file
—Hit rate
—Pay at risk
—Say-on-pay
—Airtime on calls
Beat
0
Met
0
Missed
0
Withdrawn
0
Still open
0
Answers on calls
0
Questions dodged
0
Dodges / 100 answers
—

Personal and ownership data

Full name
Michael I. Halstead
Age
53src
Education
BA International Relations, Boston Universitysrc

Not on file yet: born, place of birth, citizenship, marital status.

Shares held
168,568 HELP, 2026-09-21src
Stake value
$2.3m
Traded, 12 months
bought $1.3m, sold $0src

What to weigh

Watch 3

  • Arrived 2026-08-03 as the fourth person to run the company in eleven months, a few months before the Q4 2026 APPROACH Phase 3 readoutsrc
  • 28.4% of votes withheld on his first election as director on 2026-09-22src
  • His salary, bonus target and any sign-on terms are not disclosed in any document read; the circular pre-dates his first pay yearsrc

In their favour 2

  • Put about $1.35m of his own money into the stock (100,000 shares at a $13.47 average) on 2026-09-21src
  • Has done the clinical-to-commercial transition in the same therapeutic area (CNS, adjunctive MDD) at Intra-Cellularsrc

Pay

Bonus pays on
—
Long-term award pays on
1,075,000 RSUs vesting in three equal annual instalments from 2027-08-03; 283,334 PSUs vesting in two tranches when the share price reaches set levelssrc
  • Pay at risk not on file
  • Pays on returns tsr, time only
  • Shareholder vote not on file
  • Pay vs profit not on file

Career

  1. 2026-08 – now
    Cybin Inc. (Helus Pharma)src
    Chief Executive Officer; director from 2026-09-22
  2. 2024-03 – 2025-04
    Intra-Cellular Therapiessrc
    President
    Promoted 2024-03-19; the Helus release says he led the $14.6bn sale to Johnson & Johnson, which closed in April 2025 per PR-2026-08-18
  3. 2019-01 – 2024-03
    Intra-Cellular Therapiessrc
    Executive Vice President, General Counsel & Secretary
  4. 2014-07 – 2018-12
    Intra-Cellular Therapiessrc
    Senior Vice President, General Counsel & Secretary
    Joined 2014-07-29
  5. 2005-07 – 2013-12
    Warner Chilcott plcsrc
    Leadership positions, finishing as SVP Corporate Development (corporate development, legal, HR)
    Directed the $3bn purchase of Procter & Gamble's pharmaceutical business (2009) and the $8.5bn sale to Actavis (2013), per PR-2026-08-03

Undated in the sources

  • Davis Polk & Wardwellsrc, Corporate associate, M&A group

Not located: January to July 2014 (between Warner Chilcott and Intra-Cellular) and April 2025 to August 2026 (after the J&J closing) not located in any source searched; the Davis Polk years are not dated

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Background

  • Other Trained as a lawyer; his career has been in legal, corporate development and general management, and Helus is his first CEO rolesrc
  • Other Has brought in former Intra-Cellular colleagues: Regina Donohue as Chief People Officer and Suresh Durgam, Intra-Cellular's former CMO, to the Scientific Advisory Boardsrc
  • Other Not independent as a director; resident in New Jersey, per the 2026 circularsrc

Sources9